Re-treatment with radium-223: first experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone metastases

Overview of attention for article published in Annals of Oncology, July 2017

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (85th percentile)
Good Attention Score compared to outputs of the same age and source (73rd percentile)

Mentioned by

twitter: 16 X users

guideline: 1 clinical guideline source

Readers on

mendeley: 84 Mendeley

So far, Altmetric has seen 19 X posts from 16 X users, with an upper bound of 32,520 followers.

RT @OncoblogBulbul: Re-treatment with radium-223: first experience from a phase I/II study in patients with CRPC and bone metastases http…

Re-treatment with radium-223: first experience from a phase I/II study in patients with CRPC and bone metastases https://t.co/QoSWsgQKYW

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 15 additional X posts.